[1]施 敏,张红芬,陈 红,等.补血升白方联合针刺三阴交对直肠癌术后化疗药物所致患者白细胞减少症的影响[J].陕西中医,2022,(11):1621-1624.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.031]
　SHI Min,ZHANG Hongfen,CHEN Hong,et al.Clinical study of Buxue Shengbai prescription combined with acupuncture Sanyinjiao on leukopenia caused by chemotherapy drugs after rectal cancer operation[J].,2022,(11):1621-1624.[doi:DOI:10.3969/j.issn.1000-7369.2022.11.031]
点击复制

补血升白方联合针刺三阴交对直肠癌术后化疗药物所致患者白细胞减少症的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2022年11期
页码:
1621-1624
栏目:
针灸经络
出版日期:
2022-11-05

文章信息/Info

Title:
Clinical study of Buxue Shengbai prescription combined with acupuncture Sanyinjiao on leukopenia caused by chemotherapy drugs after rectal cancer operation
作者:
施 敏; 张红芬; 陈 红; 王 锦; 高 蔚; 卢 昕
(武汉市第一医院胃肠外科,湖北 武汉 430022)
Author(s):
SHI Min; ZHANG Hongfen; CHEN Hong; WANG Jin; GAO Wei; LU Xin
(Department of Gastrointestinal Surgery,Wuhan First Hospital,Wuhan 430022,China)
关键词:
白细胞减少症;  直肠癌术后;  补血升白方;  针刺;  三阴交;  化疗
Keywords:
Leucopenia;  Postoperative rectal cancer;  Buxue Shengbai prescription;  Acupuncture;  Sanyinjiao;  Chemotherapy
分类号:
R 557.1
DOI:
DOI:10.3969/j.issn.1000-7369.2022.11.031
文献标志码:
A
摘要:
目的:分析应用补血升白方联合针刺三阴交治疗直肠癌术后化疗所致白细胞减少症疗效及对患者免疫细胞因子的影响。方法:将120例直肠癌术后化疗所致白细胞减少症患者随机分为两组,对照组接受西医常规治疗,观察组在对照组基础上应用补血升白方联合针刺三阴交,每组60例。分析两组中医症候积分、白细胞计数(WBC)、蛋白水平及免疫细胞因子水平。比较两组疗效及不良反应发生率。结果:治疗1、2周后,观察组中医证候积分低于对照组,KPS评分高于对照组,差异具有统计学意义(均P<0.05)。治疗1、2周后,观察组WBC、中性粒细胞计数(NE)、总蛋白(TP)、白蛋白(Alb)及前蛋白(PA)水平高于对照组,差异具有统计学意义(均P<0.05)。治疗1、2周后,观察组白细胞介素2(IL-2)水平高于对照组,白细胞介素17(IL-17)、肿瘤坏死因子-α(TNF-α)水平低于对照组,差异具有统计学意义(均P<0.05)。观察组治疗总有效率为88.33%,对照组治疗总有效率为71.67%,观察组高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:补血升白方联合针刺三阴交可提高直肠癌术后化疗所致白细胞减少症的治疗效果,改善免疫细胞因子水平。
Abstract:
Objective:To analyze the effect of Buxue Shengbai prescription combined with acupuncture at Sanyinjiao and its effect on immune cytokines in the treatment of leukopenia caused by postoperative chemotherapy for rectal cancer.Methods:120 patients with leukopenia caused by postoperative chemotherapy for rectal cancer were randomly divided into two groups.The control group received conventional western medicine treatment,and the observation group was treated with Buxue Shengbai prescription combined with acupuncture Sanyinjiao on the basis of the control group,60 cases in each group.The changes of clinical symptoms,white blood cell count(WBC),protein level and immune cytokines were analyzed.The efficacy and incidence of adverse reactions were compared between the two groups.Results:After 1 and 2 weeks of treatment,the TCM syndrome score of the observation group was lower than that of the control group,and the KPS score was higher than that of the control group,and the differences were statistically significant(all P<0.05).After 1 and 2 weeks of treatment,the levels of WBC,neutrophil count(NE),total protein(TP),albumin(Alb)and preprotein(PA)in the observation group were higher than those in the control group,the differences were statistically significant(all P<0.05).After 1 and 2 weeks of treatment,the levels of interleukin-2(IL-2)in the observation group were higher than those in the control group,and the levels of interleukin-17(IL-17)and tumor necrosis factor-α(TNF-α)in the observation group were lower than those in the control group,the differences were statistically significant(all P<0.05).The total effective rate of the observation group was 88.33%,and that of the control group was 71.67%.The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Buxue Shengbai prescription combined with acupuncture Sanyinjiao can improve the therapeutic effect of leukopenia caused by postoperative chemotherapy for rectal cancer and improve the level of immune cells.

参考文献/References:

[1] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)肿瘤放化疗相关中性粒细胞减少症规范化管理指南(2021)[J].临床肿瘤学杂志,2021,26(7):638-648.
[2] 林诗舟,王萌萌,吴 焱.全国七城市妇科肿瘤化疗所致中性粒细胞减少的治疗用药分析[J].中国药物与临床,2020,20(20):3379-3383.
[3] 王运红,范海涛,李 宇,等.乳腺癌药物治疗致中性粒细胞减少的影响因素分析及重组人粒细胞集落刺激因子使用评价[J].中国药业,2022,31(11):111-115.
[4] 沈富林,孙 云.中医辨证施治治疗放化疗白细胞减少症的临床研究[J].四川医学,2014,35(2):239-241.
[5] 田劭丹,董 青,祁 烁,等.化疗后白细胞减少症中医药防治与评估专家共识[J].现代中医临床,2018,25(3):1-6.
[6] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:173-177.
[7] 李高勤,雍文兴,张志明,等.肿瘤患者放化疗导致骨髓抑制的机制[J].医药前沿,2020,10(1):10-12.
[8] 袁 理,向 淼,张思奇,等.实体恶性肿瘤骨转移患者放化疗后的骨髓抑制研究[J].实用医院临床杂志,2022,19(2):43-46.
[9] 中国临床肿瘤学会指南工作委员会.肿瘤放化疗相关中性粒细胞减少症规范化管理指南[J].中华肿瘤杂志,2017,39(11):868-878.
[10] 万晓燕.芪术茯苓汤治疗恶性肿瘤化疗后白细胞减少临床研究[J].陕西中医,2019,40(1):100-102.
[11] 吕丽媛,吕 鹏,段 赟,等.芪胶升白胶囊防治肺癌化疗所致白细胞减少症(气血两虚证)多中心、随机对照临床研究[J].世界中医药,2021,16(19):2915-2921,2926.
[12] 崔久嵬,卓文磊,黄 岚,等.肿瘤免疫营养治疗指南[J].肿瘤代谢与营养电子杂志,2020,7(2):160-168.
[13] 段惠龙.不同介入栓塞化疗方案联合射频消融治疗原发性肝癌疗效及对患者免疫功能的影响[J].陕西医学杂志,2018,47(10):1303-1305.
[14] 梁 华,张君成,李奇玮,等.四君子汤及其加味方防治肿瘤的机制研究进展[J].中医药学报,2022,50(1):86-90.
[15] 陈鑫丽,李 权,刘笑静.四君子汤加减对气阴两虚型中晚期肺癌化疗患者骨髓抑制的影响及其机制探讨[J].中国基层医药,2021,28(6):815-819.
[16] 丁 欢,吴承杰,潘娅岚,等.黄芪及当归改善化疗后骨髓抑制的分子机制研究进展[J].中国医药导报,2020,17(5):23-26.
[17] 王璐瑶,张培彤,林月洁,等.基于数据挖掘和网络药理学探讨肺癌化疗后骨髓抑制的用药规律及作用机制[J].湖南中医药大学学报,2022,42(3):418-424.
[18] 鄢国清,易 成,薛 红,等.针灸治疗肿瘤研究进展[J].陕西中医,2020,41(4):547-549.
[19] 游 怡.扶正解毒方联合针刺治疗结直肠癌术后化疗患者癌因性疲乏疗效及对外周血T细胞亚群、血清免疫球蛋白的影响[J].现代中西医结合杂志,2020,29(6):598-601,651.
[20] 戴玲玲,孟 鹏,毛俊俊,等.仙芪扶正颗粒联合三焦针法对Ⅲ-Ⅳ期结直肠癌患者免疫及CEA、CA724的影响[J].世界中医药,2020,15(20):3074-3078.

备注/Memo

备注/Memo:
基金项目:武汉市卫生健康委员会科研项目(WX15C31)
更新日期/Last Update: 2022-11-09